F-Prime featured prominently this week with a series of new and legacy portfolio highlights spanning decentralized finance, clinical AI, and gene therapy. The firm underscored its role in early-stage financings while also drawing attention to scientific recognition tied to a long-standing biotech investment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
F-Prime publicized its participation in a $4 million seed round for 3F, a decentralized finance protocol focused on linking off‑chain investment funds with on‑chain DeFi lending markets. 3F aims to reduce friction between real-time DeFi systems and traditional assets, seeking to improve utility, accessibility, and capital efficiency for tokenized funds.
This investment supports F-Prime’s exposure to infrastructure that bridges traditional finance and blockchain-based markets. By backing technology that connects institutional-grade investment vehicles with DeFi lending, the firm is positioning itself in segments that could benefit if tokenization and DeFi adoption expand in conventional capital markets.
In healthcare, F-Prime led a $10 million seed round for Almanac Health, a clinical artificial intelligence platform emerging from stealth. Almanac is designed to provide research-validated, specialist-grade clinical decision support at the point of care and to integrate directly with existing electronic health record systems.
The firm highlighted that Almanac’s founder and CEO, Cyril Zakka, M.D., previously published NEJM AI work on retrieval-augmented generation in clinical medicine. This research-driven foundation, combined with a focus on safety, validation, and workflow integration, may differentiate Almanac in a crowded clinical AI landscape and align with provider demand for embedded decision support.
F-Prime also spotlighted its earlier investment in RhyGaze, following news that CEO Katherine High, M.D., and collaborators received the 2026 Breakthrough Prize in Life Sciences. The prize recognizes their development of the first U.S. FDA-approved gene therapy for a genetic disease, targeting inherited retinal degeneration.
The recognition reinforces F-Prime’s positioning in ophthalmology and gene therapy, a field with significant long-term potential but notable regulatory and reimbursement complexity. Overall, the week underscored F-Prime’s strategy of backing high-impact platforms across DeFi, clinical AI, and genetic medicines, reinforcing its profile in both frontier technology and life sciences.